Impact of universal vaccination against hepatitis B: The Italian model

Hepatitis Monthly

Volumn 12, Issue 7, 2012, Pages 59-61

  Coppola, Rosa Cristina ^a   Meloni, Angelo ^a   Campagna, Marcello ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Hepatitis B Virus; Italy; Vaccination

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; VIRUS DNA;

ANTIBODY TITER; EDITORIAL; HEPATITIS B; HUMAN; INCIDENCE; ITALY; LIVER CELL CARCINOMA; POST EXPOSURE PROPHYLAXIS; PREVALENCE; VACCINATION;

EID: 84864232156     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6396     Document Type: Editorial

References (27)

1. Spada E, Mele A, Ciccozzi M, Tosti ME, Bianco E, Szklo A, et al. Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. Dig Liver Dis. 2001;33(9):778-84.
2. World Health Organization. Global Alert and Response: Hepatitis C. 2010 [updated 2010; cited 2010]; Available from: http://www. who.int/csr/disease/hepatitis/whocdscsrlyo%202003/en/index. html.
3. Buffington J, Mast E. Viral Hepatitis. In: Wallace RB, Kohatsu N, editors. Maxcy-Rosenau-Last Public Health & Preventive Medicine 15 ed. New York McGraw-Hill Medical; 2008. p. 1367.
4. Crovari P. Epidemiology of viral hepatitis B in Italy. Vaccine. 1995;13 (Suppl 1):S26-30.
5. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38(10 Suppl 3):S158-68.
6. Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis. 2005;37(8):622-7.
7. L. Compulsory vaccination against hepatitis B. Journal [serial on the Internet]. 1991 Date; 1: Available from: http://www.bioprevenzione. it/allegati/1182848325.pdf.
8. Bonanni P, Pesavento G, Bechini A, Tiscione E, Mannelli F, Benucci C, et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine. 2003;21(7-8):685-91.
9. Salleras L, Dominguez A, Bruguera M, Cardenosa N, Batalla J, Carmona G, et al. Dramatic decline in acute hepatitis B infection and disease incidence rates among adolescents and young people after 12 years of a mass hepatitis B vaccination programme of pre-adolescents in the schools of Catalonia (Spain). Vaccine. 2005;23(17-18):2181-4.
10. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26(49):6266-73.
11. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366(9494):1379-84.
12. Plotkin SA, Orenstein WA, Offit PA. Vaccines. Philadelphia, Pa.: Saunders/Elsevier; 2008.
13. Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, Chiu TY, et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology. 2010;51(5):1547-54.
14. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011;53(1):68-75.
15. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis. 2008;197(10):1419-26.
16. van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One. 2007;2(8):e753.
17. Dentinger CM, McMahon BJ, Butler JC, Dunaway CE, Zanis CL, Bulkow LR, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J. 2005;24(9):786-92.
18. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142(5):333-41.
19. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study. J Infect Dis. 1997;175(3):674-7.
20. Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, et al. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3216-23.
21. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine. 2006;24(5):572-7.
22. Rosado MM, Scarsella M, Pandolfi E, Cascioli S, Giorda E, Chionne P, et al. Switched memory B cells maintain specific memory independently of serum antibodies: the hepatitis B example. Eur J Immunol. 2011;41(6):1800-8.
23. Chang HC, Yen CJ, Lee YC, Chiu TY, Jan CF. Seroprevalence of hepatitis B viral markers among freshmen--20 years after mass hepatitis B vaccination program in Taiwan. J Formos Med Assoc. 2007;106(7):513-9.
24. Chen CY, Hsu HY, Liu CC, Chang MH, Ni YH. Stable seroepidemiology of hepatitis B after universal immunization in Taiwan: A 3-year study of national surveillance of primary school students. Vaccine. 2010;28(34):5605-8.
25. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336(26):1855-9.
26. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology. 2007;132(4):1287-93.
27. Campagna M, Siddu A, Meloni A, Murru C, Masia G, Coppola RC. Epidemiological Impact of Mandatory Vaccination against Hepatitis B in Italian Young Adults. Hepat Mon. 2011;11(9):750-2.